Korro Bio (KRRO) Income from Continuing Operations (2018 - 2026)
Korro Bio's (KRRO) quarterly Income from Continuing Operations came in at 19625000.0 in Q1 2026, up 16.09% YoY from 16905590.45 in Q1 2025, and down 121.12% on a QoQ basis from 92901000.0 in Q4 2025.
Korro Bio (KRRO) Income from Continuing Operations (2018 - 2026) Analysis & Trends
Korro Bio (KRRO) has 9 years of Income from Continuing Operations data on file, last reported at 19625000.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 16.09% year-over-year to 19625000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 29445000.0 (up 852.88% YoY) and the FY2025 annual result came in at 25683000.0, up 31807.41% from the prior year.
- Income from Continuing Operations eased to 19625000.0 in Q1 2026, from 92901000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 92901000.0 in Q4 2025 to a low of 25770000.0 in Q2 2025.
- A 5-year average of 7836882.35 and a median of 19605000.0 in 2023 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2023 — Income from Continuing Operations plunged 511.02% — and 2024, when it jumped 345.03%.
- Tracing KRRO's Income from Continuing Operations over 5 years: stood at 6186000.0 in 2022, then sank by 511.02% to 25426000.0 in 2023, then jumped by 345.03% to 62301000.0 in 2024, then jumped by 49.12% to 92901000.0 in 2025, then tumbled by 121.12% to 19625000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 19625000.0 (Q1 2026), 92901000.0 (Q4 2025), and 18061000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Korro Bio | 231.77 Mn | 116.73 Mn | - | -18.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -18.92 Mn |
| Mar 31, 2026 | -19.63 Mn |
| Dec 31, 2025 | 92.90 Mn |
| Sep 30, 2025 | -18.06 Mn |
| Jun 30, 2025 | -25.77 Mn |
| Mar 31, 2025 | -23.39 Mn |
| Dec 31, 2024 | 62.30 Mn |
| Sep 30, 2024 | -21.00 Mn |
| Jun 30, 2024 | -21.83 Mn |
| Mar 31, 2024 | -19.56 Mn |
| Dec 31, 2023 | -25.43 Mn |
| Sep 30, 2023 | -18.49 Mn |
| Jun 30, 2023 | -17.65 Mn |
| Mar 31, 2023 | -19.61 Mn |
| Dec 31, 2022 | 6.19 Mn |
| Sep 30, 2022 | -19.55 Mn |
| Jun 30, 2022 | -21.29 Mn |
| Mar 31, 2022 | -23.39 Mn |
| Dec 31, 2021 | -21.50 Mn |
| Sep 30, 2021 | -25.16 Mn |